| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d7cb90629802a513fb0e36b31bc2052 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 |
| filingDate |
2016-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bda157c42bac767ca27a5e0ba7de22e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_feba9381da74117baa69a376a03e2a90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e876a6125539feaadcc8b2753493ffe4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6833c14abed85a63e60d17d1288ea146 |
| publicationDate |
2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2742373-C2 |
| titleOfInvention |
Combination of tasquinimod or its pharmaceutically acceptable salt and pd-1 and/or pd-l1 inhibitor for use as a medicinal agent |
| abstract |
FIELD: pharmaceuticals.SUBSTANCE: present invention refers to a combination containing Tasquinimod or its pharmaceutically acceptable salt and PD-1 and/or PD-L1 inhibitor for use as a drug. Disclosed is use of a combination comprising Tasquinimod or a pharmaceutically acceptable salt thereof and an anti-PD-1 and/or PD-L1 antibody, for treating bladder cancer. What is also presented is a pharmaceutical composition containing said combination, a combined preparation, kit and method of treating bladder cancer using said combination.EFFECT: technical result is the disclosed combination of Tasquinimod or its pharmaceutically acceptable salt and the anti-PD-1 and/or PD-L1 antibody blocks the tumor proliferation in a synergetic way.23 cl, 9 dwg, 7 ex |
| priorityDate |
2015-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |